Genmab - ADR

Genmab A/S operates as an international biotechnology company. The firm develops human antibody therapeutics for the treatment of cancer and other diseases. Its product pipeline include daratumumab, marketed as DARZALEX for the treatment of certain indications of multiple myeloma; teprotumumab-trbw marketed as TEPEZZA for the treatment of thyroid eye disease; and ofatumumab, marketed as Arzerra for the treatment of certain indications of chronic lymphocytic leukemia. The company was founded by Donald Lee Drakeman, Florian Schonharting, and Jan G. J. van de Winkel on June 11, 1998 and is headquartered in Copenhagen, Denmark.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Genmab A/S is an international biotechnology company, which engages in the development of human antibody therapeutics for the treatment of cancer and other diseases. Its product pipeline includes daratumumab, marketed as DARZALEX for the treatment of certain indications of multiple myeloma; teprotumumab-trbw marketed as TEPEZZA for the treatment of thyroid eye disease; and ofatumumab, marketed as Arzerra for the treatment of certain indications of chronic lymphocytic leukemia. The company was founded by Donald Lee Drakeman, Florian Schonharting, and Jan G. J. van de Winkel on June 11, 1998, and is headquartered in Copenhagen, Denmark.

August 3 , 202 3 Copenhagen, Denmark; Interim Report for the First Six Months Ended June 30, 2023

Genmab Announces Financial Results for the First Half of 2023

Company Announcement COPENHAGEN , Denmark; July 2 8 , 20 2 3 – Genmab A/S ( Nasdaq: GMAB ) announced today its preliminary first half 2023 financial results and its updated 2023 financial guidance. Preliminary First Half 2023 Financial Results In the first half of 2023, Genmab's revenue increased by 34% and operating profit increased by 10%, compared to the first half of 2022 primarily due to higher product royalties.

Genmab Updates 2023 Financial Guidance

Novo Nordisk

Vertex Pharmaceuticals

Biotechnology is one of the most exciting and innovative sectors in the market, offering investors the potential for high returns coupled with groundbreaking discoveries. However, due to regulatory hurdles, clinical failures and intense competition, biotech investing also comes with high risks.

3 Biotech Stocks You Better Be Buying on Each and Every Dip

COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of conditional marketing authorization for epcoritamab (TEPKINLY®) as a monotherapy for the treatment of adult patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The final European Commissio.

Genmab Announces AbbVie Receives Positive CHMP Opinion for Epcoritamab (TEPKINLY®) for the Treatment of Adults with Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)

Company Announcement Net sales of DARZALEX ® in the second quarter of 202 3 totaled USD 2,431 million Genmab receives royalties on worldwide net sales from Janssen Biotech, Inc. (Janssen) COPENHAGEN, Denmark; July 20 , 2023 – Genmab A/S (Nasdaq: GMAB) announced today that worldwide net trade sales of DARZALEX ® (daratumumab), including sales of the subcutaneous (SC) product ( daratumumab and hyaluronidase-fihj , sold under the tradename DARZALEX FASPRO ® in the U.S. ) , as reported by Johnson & Johnson were USD 2,431 million i n the second quarter of 202 3 . Net trade sales were USD 1,322 million in the U.S. and USD 1,110 million in the rest of the world.

Genmab Announces Net Sales of DARZALEX® (daratumumab) for Second Quarter of 2023

Puma Biotechnology

Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Puma Biotech (PBYI) and Genmab A/S Sponsored ADR (GMAB). But which of these two stocks is more attractive to value investors?

PBYI vs. GMAB: Which Stock Should Value Investors Buy Now?

Artificial intelligence (AI) has become an invaluable tool for investors seeking opportunities in the stock market. Its ability to analyze large amounts of data and recognize patterns makes it an ally in identifying high-potential stocks.

3 Biotech Stocks That AI is Loving in July

AbbVie

In clinical trials, epcoritamab proved highly effective in treating a certain kind of lymphoma. The cancer drug, developed jointly by AbbVie and Genmab, has a huge potential market.

Could This New Drug Be a Blockbuster for These 2 Pharma Collaborators?

Genmab's stock has seen negative price action despite the FDA approval of its drug, Epcoritamab, for relapsed/refractory diffuse large B-cell lymphoma (DLBCL). The market has already priced in the approval, and the drug faces a competitive landscape with rivals Roche and Regeneron expected to file for their own bispecifics in r/r DLBCL in 2023. Genmab's mid-stage assets offer limited short-term catalysts to drive investor interest.

Genmab: Epkinly's Approval Not Big Enough Needle-Mover (Neutral)

COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) and AbbVie (NYSE: ABBV) today announced topline results from the follicular lymphoma (FL) cohort of the phase 1/2 EPCORE™ NHL-1 clinical trial evaluating epcoritamab (DuoBody® CD3xCD20), an investigational T-cell engaging bispecific antibody administered subcutaneously. The study cohort includes 128 adult patients with relapsed/refractory follicular lymphoma (FL) who received at least two prior lines of systemic therapy. 70.3 perce.

Genmab and AbbVie Announce Positive Topline Results from Phase 1/2 EPCORE™ NHL-1 Trial Evaluating Epcoritamab (DuoBody® CD3xCD20) in Patients with Relapsed/Refractory Follicular Lymphoma (FL)

-  Based on the topline results of epcoritamab from the EPCORE™ NHL-1 clinical trial, AbbVie and Genmab will engage global regulatory authorities to discuss next steps -  Additional data from the clinical trial will be presented at a future medical meeting -  Follicular lymphoma is a common form of non-Hodgkin's lymphoma and currently has limited treatment options, particularly in the relapsed/refractory setting  NORTH CHICAGO, Ill. , June 27, 2023 /PRNewswire/ -- AbbVie (NYSE: ABBV) and Genmab (Nasdaq: GMAB) today announced topline results from the follicular lymphoma (FL) cohort of the Phase 1/2 EPCORE™ NHL-1 clinical trial evaluating epcoritamab (DuoBody®-CD3xCD20), an investigational T-cell engaging bispecific antibody administered subcutaneously.

AbbVie and Genmab Announce Positive Topline Results from Phase 1/2 EPCORE™ NHL-1 Trial Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Follicular Lymphoma (FL)

COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) today announced that epcoritamab, a T-cell engaging bispecific antibody, has been added to the National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for “B-cell Lymphomas” (Version 4.2023) for third-line and subsequent therapy for patients with diffuse large B-cell lymphoma (DLBCL), including patients with disease progression after transplant or chimeric antigen receptor (CAR) T-.

Genmab Announces Epcoritamab Added to National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for ‘B-Cell Lymphomas'

COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) today announced data from its ongoing phase 1/2 EPCORE™ NHL-2 trial investigating epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously, in combination with rituximab-lenalidomide (R2) showed an overall response rate (ORR) of 98 percent and complete metabolic response (CMR) of 87 percent in response evaluable patients (n=104) with relapsed or refractory (R/R) follicular lymphoma (FL). These preliminary resu.

Genmab Showcases Data From Comprehensive Epcoritamab Development Program in Patients Across B-Cell Lymphomas at European Hematology Association (EHA) Annual Meeting 2023

Media Release COPENHAGEN, Denmark; June 6, 2023 Genmab A/S (Nasdaq: GMAB) announced today that its Chief Financial Officer Anthony Pagano will participate in a fireside chat at the Goldman Sachs 44 th Annual Global Healthcare Conference in Dana Point, CA, 11:20 AM PDT on June 13, 2023 (2:20 PM EDT / 8:20 PM CEST). A webcast of the fireside chat will be available on Genmab's website at https://ir.genmab.com/events-and-presentations#content.

Genmab to Participate in a Fireside Chat at the Goldman Sachs 44th Annual Global Healthcare Conference

Company Announcement COPENHAGEN, Denmark; May 31, 2023 – Genmab A/S (Nasdaq: GMAB) In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses the data of the transactions made in Genmab A/S (Nasdaq: GMAB) made by managerial employees and their closely associated persons.

Transactions with Shares and Linked Securities in Genmab A/S Made By Managerial Employees and Their Closely Associated Persons

Genmab A/S (Nasdaq: GMAB) announced today that multiple abstracts evaluating epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously, will be presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, being held in Chicago, IL and virtually, June 2-6, 2023, and at the 2023 European Hematology Association (EHA) Congress, being held in Frankfurt, Germany and virtually, June 8-11, 2023.

Genmab Announces Multiple Abstracts to be Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting and European Hematology Association (EHA) Congress

The U.S. Food and Drug Administration has approved AbbVie Inc and Danish drugmaker Genmab's experimental blood cancer therapy for adult patients who have received at least two prior lines of treatment, the companies said on Friday.

US FDA approves Genmab-AbbVie's blood cancer therapy

COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) today announced that the U.S. Food and Drug Administration (FDA) has approved EPKINLY™ (epcoritamab-bysp) as the first and only T-cell engaging bispecific antibody for the treatment of adult patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS), including DLBCL arising from indolent lymphoma, and high-grade B‑cell lymphoma, after two or more lines of systemic therapy. EPKINL.

EPKINLY™ (epcoritamab-bysp) Approved by U.S. Food and Drug Administration as the First and Only Bispecific Antibody to Treat Adults with Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)

Genmab A/S (GMAB) Q1 2023 Earnings Conference Call May 10, 2023 12:00 PM ET Company Participants Jan van de Winkel - Co-Founder, President & CEO Anthony Pagano - EVP & CFO Conference Call Participants Michael Schmidt - Guggenheim Securities Peter Welford - Jefferies Emily Field - Barclays Bank Rajan Sharma - Goldman Sachs Group James Gordon - JPMorgan Chase & Co. Matthew Phipps - William Blair & Company Yaron Werber - TD Cowen Asthika Goonewardene - Truist Securities Peter Verdult - Citigroup Operator Hello, and welcome to the Genmab's First Quarter 2023 Financial Results Conference Call. As a reminder, this conference call is being recorded.

Genmab A/S (GMAB) Q1 2023 Earnings Call Transcript

May 10 , 202 3 Copenhagen, Denmark; Interim Report for the First Quarter Ended March 31, 2023

Genmab Announces Financial Results for the First Quarter of 2023

Amphastar Pharma

Catalyst Pharmaceuticals

Genelux Corp

The top five biotech stocks today have several commonalities: strong ratings. Some also show promising charts and are Tech Leaders.

The Cream Of The Crop: 5 Biotech Stocks That Outrank Most Stocks

Company Announcement C OPENHAGEN , Denmark; April 24 , 20 2 3 – Genmab A/S ( Nasdaq: GMAB ) announced today its decision to file a request for review of the award dismissing its claims in the second arbitration arising under its license agreement with Janssen Biotech, Inc. for daratumumab. The review of the award will be conducted by a single appeal arbitrator under the rules of the CPR Institute for Dispute Resolution for Non-Administered Arbitration.

Genmab To File Appeal in Its Second Arbitration Under License Agreement with Janssen

Company Announcement COPENHAGEN , Denmark; April 21 , 20 2 3 – Genmab A/S ( Nasdaq: GMAB ) announced today an award in the second arbitration arising under its license agreement with Janssen Biotech, Inc. (Janssen) for daratumumab. The arbitral tribunal dismissed Genmab's claims, on the basis that they should have been brought in the first arbitration.

Genmab Announces Initial Resolution of Its Second Arbitration Under License Agreement with Janssen

Company Announcement Net sales of DARZALEX ® in the first quarter of 202 3 totaled USD 2,264 million Genmab receives royalties on worldwide net sales from Janssen Biotech, Inc. (Janssen) COPENHAGEN, Denmark; April 18 , 2023 – Genmab A/S (Nasdaq: GMAB) announced today that worldwide net trade sales of DARZALEX ® (daratumumab), including sales of the subcutaneous (SC) product ( daratumumab and hyaluronidase-fihj , sold under the tradename DARZALEX FASPRO ® in the U.S. ) , as reported by Johnson & Johnson were USD 2,264 million i n the first quarter of 202 3 . Net trade sales were USD 1,191 million in the U.S. and USD 1,072 million in the rest of the world.

Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2023

argenx

Media Release COPENHAGEN, Denmark; April 1 7 , 2023 Genmab and  argenx   have entered a multiyear collaboration bringing together capabilities to jointly discover, develop and commercialize antibody therapies Discovery programs against two differentiated targets are underway    Genmab A/S  (Nasdaq: GMAB) and argenx  (Euronext & Nasdaq: ARGX) announced today that Genmab and  argenx  have entered into a collaboration agreement to jointly discover, develop and commercialize novel therapeutic antibodies with applications in immunology , as well as i n oncology therapeutic areas. The multiyear collaboration will leverage the antibody engineering expertise and knowledge of disease biology of both companies to accelerate the identification and development of novel antibody therapeutic candidates with a goal to address unmet patient needs in immunology and cancer.

News for Genmab - ADR Stock (GMAB)